The Readout Loud

324 Episodes

1. 282: Lilly’s obesity drug, the power of radiation, & a biotech implosion

   Published: 09/11/2023
2. 281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO

   Published: 02/11/2023
3. 280: ESMO highlights, Roivant's big deal, & biotech VC on the rise

   Published: 26/10/2023
4. 279: Live from the 2023 STAT Summit

   Published: 19/10/2023
5. 278: Merger Mondays, Ozempic panic, & CRISPR'd pigs

   Published: 12/10/2023
6. 277: Is the Nobel committee evolving? Plus, preventing public health's wiliest virus

   Published: 05/10/2023
7. 276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump

   Published: 28/09/2023
8. 275: A thorny ALS debate at the FDA, and the promise of artificial wombs

   Published: 21/09/2023
9. 274: Covid’s latest surge, Alnylam at the FDA, & the end of an era

   Published: 14/09/2023
10. 273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter

    Published: 07/09/2023
11. 272: Vivek's star turn, leaky drug data, & biotech as family business

    Published: 24/08/2023
12. 271: Racing for gene therapy, a pioneering approval, & startups in the lurch

    Published: 18/08/2023
13. 270: Your guide to Wegovy’s blockbuster heart study

    Published: 10/08/2023
14. 269: Biotech layoffs, eye drug drama, & gene therapy milestones

    Published: 03/08/2023
15. 268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading

    Published: 27/07/2023
16. 267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford

    Published: 20/07/2023
17. 266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads

    Published: 13/07/2023
18. 265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market

    Published: 29/06/2023
19. 264: Messy PBM conflicts, debatable vaccines, & the future of flu season

    Published: 22/06/2023
20. 263: Biogen's messy board, Laronde's data problem, & the downside of a boom

    Published: 15/06/2023